T10 soluble complement receptor 1: Began a Phase I, dose-escalating trial in patients scheduled for thrombolytics or angioplasty, to determine safety and pharma

T Cell Sciences Inc. (TCEL), Needham, Mass. Product: T10 soluble complement receptor 1, a recombinant protein that inhibits complement activation, minimizing blood vessel leakage and activation of ne...